Department of Clinical Pharmacology, the Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, and the Department of Endocrinology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, the Department of Obstetrics and Gynecology, Copenhagen University Hospital Hvidovre, Hvidovre, the Institute of Clinical Medicine, University of Copenhagen, Copenhagen, the Department of Rheumatology, Copenhagen University Hospital Glostrup, Glostrup, and the Department of Cardiology, Copenhagen University Hospital Hillerød, Hillerød, Denmark.
Corresponding author: Anne Mette Skov Sørensen, Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; email: [email protected].
Supported by Helsefonden (Grant number: 18-B-0225I), Aase og Ejnar Danielsens Fond (grant no.: 18-10-0527), and Tværspuljen (grant no.: P-2019-2-11). The funding sources were not involved in the conduct of the research.
Financial Disclosure Espen Jimenez-Solem has performed research sponsored by Eli Lilly, Johnson & Johnson, Gilead, and Vertex Pharmaceuticals. The other authors did not report any potential conflicts of interest.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at https://links.lww.com/AOG/C624.
